Whether reimbursement discussions for the PIK3CA gene-targeting anticancer drug ‘Piqray’ will make progress is gaining attention.

According to industry sources, Novartis Korea’s Piqray (alpelisib) is expected to be deliberated at the coming Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee meeting. The drug had been unable to pass deliberations from the same committee in February last year and had refiled an application for reimbursement at the end of last year.

However, based on CDDC’s A8 country assessment results that were disclosed after the meeting, reimbursement standards discussed this time will be narrowed to PIK3CA mutation-positive pati